The study also concluded significant effect of Dipeptidyl peptidase-4 inhibitor on reduction of hospitalization, lipid profile and also ASCVD risk score of type-II diabetes mellitus patients regardless of clinical comorbidities. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.